Bad Behaviour by Pharma, and Unforeseen Consequences
Research Ethics Blog
APRIL 17, 2015
This is a must-read for anyone interested in the ethics of drug development and clinical trials. It explores how genuinely bad behaviour on the part of pharmaceutical companies can lead to overreaction by journalists and the public, sometimes with tragic consequences. By Matthew Herper, writing for Forbes.com: How Marketing And Media Muddled The Truth About The Heart Drug Vytorin.
Let's personalize your content